The differential response of CD276-positive ESCC PSO and CD276-negative NC PSO following iPSC CD276-targeted CAR-NK treatment indicates the on-target effect and the potential off-tumor toxicity of iPSC CD276-targeted CAR-NK in future clinical trials. The gene discussed is CD276; the disease is neoplasm.